At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 121 target
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and SI-B003 for Non-small Cell Lung Cancer and Nasopharyngeal Carcinoma. Currently recruiting, targeting 121 participants across 16 sites.
Detailed Summary
Phase II: To explore the efficacy, safety and tolerability of BL-B01D1+SI-B003 in patients with locally advanced or metastatic non-small cell lung cancer and nasopharyngeal carcinoma, and to further explore the optimal dose and mode of combination.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2Recruiting
20242025202620272028
First PostedJul 2023
Enrollment StartJan 2024
TodayJul 2026
Primary CompletionDec 2026
Study CompletionDec 2027
First PostedJul 21, 2023
Enrollment StartJan 29, 2024
Primary CompletionDec 1, 2026
Study CompletionDec 1, 2027
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 2.9 years agoPrimary completion in 5 months
Interventions
BL-B01D1drug
Administration by intravenous infusion
SI-B003drug
Administration by intravenous infusion